Therapeutic il-13 polypeptides
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsKenan Christopher Garcia, Ignacio Moraga Gonzalez
Life of this patent
Estimating the term…
Abstract
Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13Rα2, relative to the native human IL-13 protein; (b) altered affinity for IL-13Rα1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4Rα relative to the native human IL-13 protein.
Claims19
A polypeptide comprising:
- a modified interleukin 13 (IL-13) engineered to have increased affinity for interleukin 13 receptor α2 (IL-13Rα2), relative to native human IL 13 protein;
- (b) and decreased affinity for interleukin 13 receptor α1 (IL-13Rα1) relative to native human IL 13 protein;
- wherein the modified IL-13 polypeptide comprises amino acid changes relative to wild type IL-13 at positions L10, R86, D87, T88 and R108.
A modified IL-13 antagonist polypeptide engineered to have decreased affinity for interleukin 13 receptor α2 (IL-13Rα2), relative to native human IL 13 protein;
- (b) and increased affinity for interleukin 13 receptor α1 (IL-13Rα1) relative to native human IL 13 protein, wherein the modified IL-13 polypeptide comprises amino acid changes relative to wild type IL-13 at positions V18, D87, T88, L101, K104, and K105;
- and comprising amino acid substitutions E12A/G/S and R65D/E, wherein the polypeptide is conjugated or fused to a therapeutic or labeling moiety.
Dependencies are inferred from the claim text.